Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dogwood Doses First Patient in Phase 2b Halneuron Neuropathy Trial
Details : Halneuron (tetrodotoxin injectable formulation) is a selective sodium channel blocker, produces analgesia, being developed chemotherapy induced neuropathic pain.
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Maxim Group
Deal Size : $4.8 million
Deal Type : Public Offering
Dogwood Therapeutics Prices $4.8M Registered Direct Offering Under Nasdaq Rules
Details : The net proceeds from the offering will be used to advance the clinical development of Halneuron (tetrodotoxin). It is being indicated for the treatment of chemotherapy induced neuropathic pain.
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 13, 2025
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Maxim Group
Deal Size : $4.8 million
Deal Type : Public Offering
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dogwood Therapeutics Announces Dosing in Phase 2b Trial of Halneuron® for CINP
Details : Halneuron (tetrodotoxin injectable formulation) is a selective sodium channel blocker, produces analgesia, being developed chemotherapy induced neuropathic pain.
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : WEX Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Virios Therapeutics And Wex Pharmaceuticals Form Dogwood Therapeutics
Details : The combined company will be focused on Halneuron, in Phase 2b for chemotherapy-induced neuropathic pain, IMC-1, poised for Phase 3 for fibromyalgia and IMC-2 to treat Long-COVID sequelae.
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : WEX Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable